AIM To develop a contrast-enhanced ultrasound(CEUS)predictive model for distinguishing intrahepatic cholangiocarcinoma(ICC)from hepatocellular carcinoma(HCC)in
Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC)since 2007 and numerous studies have inv